AR and prostate cancer: The results of this study show that TPX2 can function as a co-activator of PXR, which is consistent with some previous studies; Zhou et al. found that TPX2 can act as a novel co-activator of ETS-1, and Sun et al. found that TPX2 can promote endocrine dependence by facilitating the upregulation of AR activity and proliferation of prostate cancer cells [17, 18].